Ubs Asset Management Americas Inc Gilead Sciences, Inc. Transaction History

Ubs Asset Management Americas Inc

$345 Billion
Q2 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 11,139,775 shares of GILD stock, worth $931 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

11,139,775

Previous 9,524,841 16.95%

Holding current value

$931 Million

Previous $698 Million 9.55%

% of portfolio

0.22%

Previous 0.25%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$63.15 - $72.88 $102 Million - $118 Million	1,614,934 Added 16.95%	11,139,775 $764 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $5.64 Million - $6.88 Million	78,816 Added 0.83%	9,524,841 $698 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $6.61 Million - $7.49 Million	90,164 Added 0.96%	9,446,025 $765 Million
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $33.3 Million - $36.4 Million	450,908 Added 5.06%	9,355,861 $701 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $36.2 Million - $41.3 Million	-468,432 Reduced 5.0%	8,904,953 $739 Million
Q4 2022 Feb 14, 2023	SELL	$62.32 - $89.47 $30.4 Million - $43.7 Million	-488,144 Reduced 4.95%	9,373,385 $805 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $38.5 Million - $43.9 Million	646,166 Added 7.01%	9,861,529 $608 Million
Q2 2022 Aug 12, 2022	SELL	$57.72 - $65.01 $149 Million - $167 Million	-2,573,580 Reduced 21.83%	9,215,363 $570 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $146 Million - $183 Million	2,527,753 Added 27.29%	11,788,943 $701 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $21.7 Million - $24.6 Million	334,255 Added 3.74%	9,261,190 $672 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $16.5 Million - $17.8 Million	244,381 Added 2.81%	8,926,935 $624 Million
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $24 Million - $26.2 Million	-377,950 Reduced 4.17%	8,682,554 $598 Million
Q1 2021 May 14, 2021	BUY	$60.0 - $68.46 $3.81 Million - $4.34 Million	63,451 Added 0.71%	9,060,504 $586 Million
Q4 2020 Mar 01, 2021	BUY	$56.65 - $64.55 $22.3 Million - $25.4 Million	392,859 Added 4.57%	8,997,053 $524 Million
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $21.7 Million - $27.3 Million	349,009 Added 4.23%	8,604,194 $544 Million
Q2 2020 Aug 14, 2020	BUY	$72.34 - $84.0 $106 Million - $124 Million	1,471,150 Added 21.69%	8,255,185 $635 Million
Q1 2020 May 15, 2020	BUY	$62.63 - $80.22 $9.97 Million - $12.8 Million	159,122 Added 2.4%	6,784,035 $507 Million
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $743,445 - $817,765	12,065 Added 0.18%	6,624,913 $430 Million
Q3 2019 Nov 14, 2019	BUY	$62.51 - $69.0 $8.11 Million - $8.96 Million	129,795 Added 2.0%	6,612,848 $419 Million
Q2 2019 Aug 15, 2019	SELL	$61.87 - $69.38 $29.6 Million - $33.2 Million	-478,760 Reduced 6.88%	6,483,053 $0
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $53.2 Million - $59.6 Million	850,855 Added 13.92%	6,961,813 $0
Q4 2018 Feb 13, 2019	BUY	$60.54 - $79.0 $11.2 Million - $14.6 Million	185,259 Added 3.13%	6,110,958 $382 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $6.89 Million - $7.63 Million	-96,705 Reduced 1.61%	5,925,699 $0
Q2 2018 Aug 14, 2018	BUY	$64.88 - $75.68 $17.6 Million - $20.5 Million	271,398 Added 4.72%	6,022,404 $0
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $14.6 Million - $17.8 Million	-199,923 Reduced 3.36%	5,751,006 $0
Q4 2017 Feb 09, 2018	SELL	$71.15 - $83.52 $26.8 Million - $31.5 Million	-376,866 Reduced 5.96%	5,950,929 $0
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $456 Million - $541 Million	6,327,795	6,327,795 $0

Others Institutions Holding GILD

# of Institutions

1,879

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Gilead Sciences, Inc. Transaction History